NeuroPace pops after pricing upsized IPO

NeuroPace

22/04/2021 18:15

** Medical device maker NeuroPace Inc  NPCE.O  jumps in its
Nasdaq debut on Thurs
    ** NPCE opens at $23.25 vs $17 IPO price, valuing co at
roughly $500 mln
    ** Co sells 6 mln shares, up from ~5.3 mln, at top of
$15-$17 filed range  urn:newsml:reuters.com:*:nGNX55qnK4
    ** NPCE raises $102 mln to support marketing of its
FDA-approved RNS System for treating epileptic seizures
    ** Debut delayed a day after co said in filing https://www.sec.gov/Archives/edgar/data/1528287/000162828021007240/neuropace-fwprecfiusmatter.htm
 early Weds it received notice from Treasury Dept regarding an
"inquiry into unspecified matters that may fall under the
jurisdiction of the Committee on Foreign Investment in the
United States (CFIUS)”
    ** NPCE said it intends to cooperate fully with CFIUS
    ** JP Morgan and Morgan Stanley leading the IPO along with
Wells Fargo and SVB Leerink as jt bookrunners

 (Lance Tupper is a Reuters market analyst. The views expressed
are his own)
 ((lance.tupper.tr.com@reuters.net
lance.tupper@tr.com 1-332-219-1430))